Despite tripling active GLP-1 levels and blocking nearly 70% of DPP-4 activity, vildagliptin failed to protect heart function or reverse cardiac remodeling in rats after a heart attack.
~3-fold GLP-1 increase, zero cardiac benefitDespite successfully tripling active GLP-1 levels, vildagliptin did not improve any measure of heart function after myocardial infarction in rats.
What the researchers found
Vildagliptin inhibited DPP-4 enzymatic activity by approximately 70% and increased active GLP-1 levels roughly 3-fold in plasma (p < 0.05 vs. untreated groups). However, ejection fraction remained equally depressed in all three MI groups compared to sham controls, regardless of whether vildagliptin was started immediately or three weeks after the heart attack.
Stress biomarkers ANP and BNP mRNA were elevated in all MI groups with no significant reduction from vildagliptin treatment. The drug also had no effect on cardiomyocyte size, capillary density, glucose levels, or body weight.
Why it matters
GLP-1 peptides have shown promise as cardioprotective agents, sparking interest in whether DPP-4 inhibitors — which raise GLP-1 by preventing its breakdown — could protect the heart after a heart attack. This study provides important negative evidence, suggesting that the modest GLP-1 increases achieved through DPP-4 inhibition may not reach the therapeutic threshold needed for cardiac protection, pointing researchers toward direct GLP-1 analogs or higher-potency approaches instead.
How the study worked
Sprague-Dawley rats underwent coronary artery ligation to induce a heart attack or sham surgery. Some MI rats received vildagliptin (15 mg/kg/day) starting 2 days before surgery (early treatment), while others started treatment 3 weeks after surgery (late treatment). Controls received no drug. At 12 weeks, researchers assessed heart function using echocardiography and invasive hemodynamic measurements, and performed molecular and tissue analysis.
What this study cannot tell us
This was an animal study in rats, so results may not directly translate to humans. The study used a single dose of vildagliptin and did not test higher doses that might produce stronger effects. The sample size was not reported in the abstract. Additionally, rats were not diabetic, so the drug's cardiac effects in the context of diabetes remain untested here.
How to read the evidence
This is a preclinical animal study using a well-established rat model of heart failure. While the methodology is sound (including sham controls, hemodynamic measurements, and molecular analysis), animal studies rank below human clinical trials in evidence hierarchies.
When this study was published
Published in 2011, this study predates the large cardiovascular outcome trials for DPP-4 inhibitors (SAVOR-TIMI, EXAMINE, TECOS) and GLP-1 receptor agonists (LEADER, SUSTAIN-6), which have since clarified the cardiovascular profiles of these drug classes.
The bigger picture
This study sits at the intersection of peptide-based diabetes drugs and cardiovascular research. While GLP-1 receptor agonists have since shown cardiovascular benefits in clinical trials, DPP-4 inhibitors have generally produced neutral cardiac outcomes in large human studies — a pattern consistent with this early animal data. The results highlight that not all strategies to increase GLP-1 signaling are equivalent when it comes to heart protection.
Questions still open
- Would direct GLP-1 receptor agonists, which achieve higher and more sustained GLP-1 signaling, produce better cardiac outcomes than DPP-4 inhibitors in the same model?
- Could higher doses of vildagliptin or combination therapy overcome the lack of cardiac benefit seen here?
- Does the timing of intervention (pre-infarction vs. post-infarction) matter more with direct GLP-1 analogs than with DPP-4 inhibitors?
Common questions
What is vildagliptin and how does it relate to GLP-1?
Why didn't boosting GLP-1 help the heart in this study?
Read the original research
Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.
Cardiovascular diabetology, 10, 85
Citation
Yin, Meimei; Silljé, Herman H W; Meissner, Maxi; van Gilst, Wiek H; de Boer, Rudolf A. (2011). Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.. Cardiovascular diabetology, 10, 85. https://doi.org/10.1186/1475-2840-10-85